Article

Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: A prospective, non-randomized, parallel, controlled study

Inflammatory Bowel Disease Centre & Department of Surgery, Yokkaichi Social Insurance Hospital, Yokkaichi, Mie, Japan.
Alimentary Pharmacology & Therapeutics (Impact Factor: 5.48). 02/2007; 25(1):67-72. DOI: 10.1111/j.1365-2036.2006.03158.x
Source: PubMed

ABSTRACT The impact of enteral nutrition on post-operative recurrence has not been properly examined.
To investigate the impact of enteral nutrition using an elemental diet on clinical and endoscopic recurrence after resection for Crohn's disease.
Forty consecutive patients who underwent resection for ileal or ileocolonic Crohn's disease were studied. After operation, 20 patients continuously received enteral nutritional therapy (EN group), and 20 had neither nutritional therapy nor food restriction (non-EN group). In the EN group, enteral formula (Elental) was infused through a nasogastric tube in the night-time, and low fat foods were taken in the daytime. All patients were followed up regularly for 1 year after operation. Ileocolonoscopy was performed at 6 and 12 months after operation.
One patient (5%) in the EN group and seven (35%) in the non-EN group developed clinical recurrence during 1-year follow-up (P = 0.048). Six months after operation, five patients (25%) in the EN group and eight (40%) in the non-EN group developed endoscopic recurrence (P = 0.50). Twelve months after operation, endoscopic recurrence was observed in six patients (30%) in the EN group and 14 (70%) in the non-EN group (P = 0.027).
Our long-term enteral nutritional therapy significantly reduced clinical and endoscopic recurrence after resection for Crohn's disease.

Download full-text

Full-text

Available from: Takayuki Yamamoto, May 28, 2014
0 Followers
 · 
84 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The majority of patients with Crohn’s disease require surgery for disease-related complications. Postoperative Crohn’s disease recurrence is common after intestinal resection. The optimal management strategy for postoperative recurrence of Crohn’s disease is controversial. In the absence of universally adopted guidelines, clinicians and patients must discuss and weigh the risks and benefits of postoperative pharmacotherapy. Those patients at low risk of disease recurrence may not require treatment. On the other hand, patients with more aggressive disease and high risk of recurrence may be best treated early in the postoperative period with an immunomodulator or antitumor necrosis factor agents. Ideally, postoperative treatment decisions would be made using predictable, reliable, and reproducible clinical prediction criteria that would guide treatment. This article reviews the data on postoperative Crohn’s disease, including predictors of early recurrence, available options for postoperative monitoring, timing of initiation, and choice of postoperative therapy for prevention and management.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Each of the medical and surgical therapies for Crohn’s disease has inherent advantages and disadvantages that must be balanced for patients with moderate to severe disease. Most patients with Crohn’s disease require surgery at some point during the lifelong illness, but surgical therapy is not curative for most patients, as postoperative recurrence of Crohn’s disease is common and can pose diagnostic and therapeutic challenges. Disease monitoring and appropriate prophylaxis are necessary in patients at high risk.
    Current Gastroenterology Reports 12/2008; 10(6):606-611. DOI:10.1007/s11894-008-0109-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: La majorité des malades atteints d’une maladie de Crohn (MC) nécessitent le recours à un traitement chirurgical à un moment donné de leur évolution. Cependant, la récidive de la maladie est la règle. Certains facteurs peuvent influencer le temps de récurrence, ainsi que la sévérité des symptômes. La connaissance de ce risque de récidive justifie le concept d’être économe en termes de résection intestinale et de discuter après la chirurgie un traitement prophylactique des rechutes. Le but de cette revue est de faire le point sur les facteurs de risque de récidive postopératoire de la MC et les thérapeutiques prophylactiques de la récidive. Les facteurs favorisant la récidive postopératoire de la MC ont fait l’objet de nombreux travaux, mais les études contrôlées sont très rares et les résultats sont parfois contradictoires. La question principale est de savoir comment prévenir la récidive postopératoire ? À côté du rôle prouvé du tabac dont l’arrêt devrait être impératif, différents médicaments: les aminosalicylés et la sulfasalazine, les métronidazoles, les immunosuppresseurs, les probiotiques et les anti-TNF-alpha ont fait l’objet de plusieurs essais thérapeutiques contrôlés. Les médicaments candidats seraient les nitro-imidazolés et les immunosuppresseurs, et de nouvelles approches thérapeutiques évaluant mieux des thérapies biologiques devraient être réalisées afin de mieux élucider leur place thérapeutique. Les attitudes sont assez claires après résection iléale ou iléocolique, elles le sont moins après résection colique ou colorectale.
    Journal Africain d?Hépato-Gastroentérologie 01/2013; DOI:10.1007/s12157-013-0475-y